Most published manufacturing protocols for anti‐tumor T cells have not found it necessary to specifically deplete Tregs.28, 29, 30, 31 However, it was unclear whether TGF‐β CAR‐T cell production might be uniquely challenging. This evidence concerns the gene TGFB1 and neoplasm.